Table 1.
Studies on rituximab-based chemotherapy that investigated both HCV reactivation and hepatic flares.
| Coppola et al., 2012 [40] | Ennishi et al., 2010 [36] | Marignani et al., 2011 [39] | Pitini et al., 2010 [38] | Tsutsumi et al., 2009 [37] | |
|---|---|---|---|---|---|
| Type of study | Observational prospective | Multicentre retrospective | Observational retrospective | Observational prospective | Observational prospective |
| Disease | LNH, CLL | LNH (DLBCL) | LNH | LNH (DLBCL, FL) | LNH (DLBCL) |
| Number of cases | 8 | 34 | 3 | 10 | 4 |
| Treatment | R-CHOP in 5 | R- and P-based | R-CHOP | RCHOP | R-CHOP in 1 |
| R-FC in 1 | chemotherapy | R-CHO in 2 | |||
| CP and then R-FC | R-THP-CO in 1 | ||||
| in 1 | |||||
| FC in 1 | |||||
| With HCV reactivation, number of cases: | 7 | 34 | 2 | 10 | 4 |
| During CT | 7 | 34 | 0 | 10 | 4 |
| After CT | 0 | 0 | 2 | 0 | 0 |
| With hepatic flare, number of cases: | 7 | The available datum (27%) refers to flares observed in 131 patients, of whom only 34 were followed up for HCV RNA | 2 | 10 | 3 |
| During CT | 7 | 0 | 10 | 3 | |
| After CT | 0 | 2 | 0 | 0 | |
NHL: non-Hodgkin lymphoma; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; CLL: chronic lymphocytic leukaemia; R-CHO: rituximab, cyclophosphamide, doxorubicin, vincristine; RFC: rituximab, fludarabine, and cyclophosphamide; CP: cyclophosphamide, prednisone; FC: fludarabine and cyclophosphamide; R-THPCOP: rituximab, pirarubicin (tetrahydropyranyl-adriamicin [TPH] ) cyclophosphamid, vincristine without prednisone.